HC Wainwright Reaffirms “Buy” Rating for AC Immune (NASDAQ:ACIU)

HC Wainwright reissued their buy rating on shares of AC Immune (NASDAQ:ACIU) in a report released on Thursday,Benzinga reports. HC Wainwright currently has a $16.00 target price on the stock.

AC Immune Price Performance

Shares of ACIU stock opened at $1.66 on Thursday. The firm has a market capitalization of $166.68 million, a price-to-earnings ratio of -3.61 and a beta of 1.49. AC Immune has a 12-month low of $1.64 and a 12-month high of $4.98. The business has a 50 day simple moving average of $2.39 and a 200 day simple moving average of $2.86.

Institutional Trading of AC Immune

Several institutional investors have recently made changes to their positions in ACIU. Quinn Opportunity Partners LLC acquired a new position in AC Immune during the 4th quarter worth $27,000. Two Sigma Advisers LP acquired a new stake in shares of AC Immune in the 4th quarter valued at $36,000. Boothbay Fund Management LLC bought a new stake in AC Immune during the 4th quarter worth approximately $38,000. RPO LLC acquired a new stake in AC Immune in the 4th quarter valued at about $51,000. Finally, Jane Street Group LLC acquired a new position in AC Immune during the 4th quarter worth $66,000. 51.36% of the stock is currently owned by institutional investors and hedge funds.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.